AU2007275067A1 - Macrocyclic compounds useful as BACE inhibitors - Google Patents
Macrocyclic compounds useful as BACE inhibitors Download PDFInfo
- Publication number
- AU2007275067A1 AU2007275067A1 AU2007275067A AU2007275067A AU2007275067A1 AU 2007275067 A1 AU2007275067 A1 AU 2007275067A1 AU 2007275067 A AU2007275067 A AU 2007275067A AU 2007275067 A AU2007275067 A AU 2007275067A AU 2007275067 A1 AU2007275067 A1 AU 2007275067A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- tetrahydro
- dioxo
- benzo
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06117571.7 | 2006-07-20 | ||
| EP06117571 | 2006-07-20 | ||
| PCT/EP2007/057540 WO2008009750A2 (en) | 2006-07-20 | 2007-07-20 | Macrocyclic compounds useful as bace inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2007275067A1 true AU2007275067A1 (en) | 2008-01-24 |
Family
ID=37467481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007275067A Abandoned AU2007275067A1 (en) | 2006-07-20 | 2007-07-20 | Macrocyclic compounds useful as BACE inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090312370A1 (enExample) |
| EP (1) | EP2046761A2 (enExample) |
| JP (1) | JP2009544599A (enExample) |
| KR (1) | KR20090039726A (enExample) |
| CN (1) | CN101490018A (enExample) |
| AU (1) | AU2007275067A1 (enExample) |
| BR (1) | BRPI0715440A2 (enExample) |
| CA (1) | CA2657280A1 (enExample) |
| MX (1) | MX2009000710A (enExample) |
| RU (1) | RU2009105762A (enExample) |
| WO (1) | WO2008009750A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325830D0 (en) * | 2003-11-05 | 2003-12-10 | Novartis Ag | Organic compounds |
| RU2007130794A (ru) * | 2005-01-13 | 2009-02-20 | Новартис АГ (CH) | Макроциклические соединения для применения в качестве ингибиторов bace |
| GB0500683D0 (en) * | 2005-01-13 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0526614D0 (en) | 2005-12-30 | 2006-02-08 | Novartis Ag | Organic compounds |
| EP2046760A1 (en) * | 2006-07-20 | 2009-04-15 | Novartis AG | Macrocyclic lactams |
| EP2881394B1 (en) | 2012-07-31 | 2018-03-21 | Kyowa Hakko Kirin Co., Ltd. | Condensed ring heterocyclic compound |
| CA2899938C (en) | 2013-02-12 | 2021-10-19 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| CN108732355B (zh) * | 2017-04-25 | 2021-06-25 | 首都医科大学附属北京安定医院 | 一种测定bace1酶切nrg1活性的检测方法及其试剂盒 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2450167A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| WO2002100856A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| GB0325830D0 (en) * | 2003-11-05 | 2003-12-10 | Novartis Ag | Organic compounds |
| RU2007130794A (ru) * | 2005-01-13 | 2009-02-20 | Новартис АГ (CH) | Макроциклические соединения для применения в качестве ингибиторов bace |
| GB0500683D0 (en) * | 2005-01-13 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0526614D0 (en) * | 2005-12-30 | 2006-02-08 | Novartis Ag | Organic compounds |
| EP2046760A1 (en) * | 2006-07-20 | 2009-04-15 | Novartis AG | Macrocyclic lactams |
| WO2008009458A1 (en) * | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
-
2007
- 2007-07-20 RU RU2009105762/04A patent/RU2009105762A/ru not_active Application Discontinuation
- 2007-07-20 AU AU2007275067A patent/AU2007275067A1/en not_active Abandoned
- 2007-07-20 KR KR1020097001065A patent/KR20090039726A/ko not_active Withdrawn
- 2007-07-20 MX MX2009000710A patent/MX2009000710A/es unknown
- 2007-07-20 CN CNA2007800274885A patent/CN101490018A/zh active Pending
- 2007-07-20 CA CA002657280A patent/CA2657280A1/en not_active Abandoned
- 2007-07-20 EP EP07819910A patent/EP2046761A2/en not_active Withdrawn
- 2007-07-20 US US12/374,467 patent/US20090312370A1/en not_active Abandoned
- 2007-07-20 WO PCT/EP2007/057540 patent/WO2008009750A2/en not_active Ceased
- 2007-07-20 JP JP2009519995A patent/JP2009544599A/ja not_active Withdrawn
- 2007-07-20 BR BRPI0715440-2A patent/BRPI0715440A2/pt not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009544599A (ja) | 2009-12-17 |
| RU2009105762A (ru) | 2010-08-27 |
| MX2009000710A (es) | 2009-01-30 |
| KR20090039726A (ko) | 2009-04-22 |
| CN101490018A (zh) | 2009-07-22 |
| WO2008009750A3 (en) | 2008-03-20 |
| US20090312370A1 (en) | 2009-12-17 |
| EP2046761A2 (en) | 2009-04-15 |
| BRPI0715440A2 (pt) | 2013-07-23 |
| CA2657280A1 (en) | 2008-01-24 |
| WO2008009750A2 (en) | 2008-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007275067A1 (en) | Macrocyclic compounds useful as BACE inhibitors | |
| JP4628366B2 (ja) | 大環状ラクタムおよびその医薬的使用 | |
| US8039455B2 (en) | Macrocyclic compounds useful as BACE inhibitors | |
| AU2007275132A1 (en) | Macrocyclic lactams | |
| US20080132477A1 (en) | Macrocyclic Compounds Useful as Bace Inhibitors | |
| US8008250B2 (en) | Macrocyclic compounds and compositions useful as BACE inhibitors | |
| US20080070885A1 (en) | Macrocyclic compounds having aspartic protease inhibiting activity and pharmaceutical uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |